Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Pravachol pediatric indication

Executive Summary

FDA approves Pravachol (pravastatin) for use in children eight and older with heterozygous familial hypercholesterolemia and "whose LDL cholesterol levels are above the indicated limits after an adequate trial of diet," Bristol-Myers Squibb says Oct. 31. Bristol will receive six months pediatric exclusivity, extending protection from generics for the statin through April 2003...

You may also be interested in...



Study Links Paclitaxel To Lower-Leg Amputations

New research links the use of stents and balloons coated with the drug paclitaxel to an increased risk of lower-leg amputation shortly following surgery. The study was conducted by Greek researcher Konstantinos Katsanos, who previously found an increased mortality risk in paclitaxel-treated patients.

New CEO Brett Monia Takes The Lead As Ionis Prioritizes Non-Partnered Programs

Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.

Smith & Nephew Boosts ENT Portfolio, Acquires Tusker Medical

Smith & Nephew has acquired Tusker Medical for an undisclosed price. The acquisition comes just months after Tusker’s Tula system was approved by the FDA as a breakthrough device.

UsernamePublicRestriction

Register

PS040717

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel